Explore the vast range of titles available.

Exosomes can be derived from a variety of biological sources and show potential application in wound healing, scar prophylaxis, photodamage prevention, skin regeneration, improved grafting success, hair loss mitigation, and as biomarkers and drug carriers. However, their widespread clinical application is hindered by cost, a complex isolation process, lack of uniform experimental protocols, and limited assessment of infective potential hinder their widespread clinical application. Abstract Introduction Exosomes are extracellular vesicles that transport bioactive substances during normal and abnormal cellular physiological processes. The unique properties of exosomes can be exploited for use as biomarkers and targeted drug delivery vehicles, and are, for this reason, gaining increasing attention in the field of dermatology. This review aims to synthesise the existing evidence supporting exosomes in regenerative and cosmetic dermatology. Method A comprehensive PubMed search for the period of 2010–2023 was performed using the MeSH terms \"exosome\" and \"skin.” The initial search yielded 246 studies, which were then refined to 178 studies following title and abstract screening. Studies were confined to human or animal studies published in English that evaluated the use of exosomes in medical/cosmetic dermatology. A subsequent full-text review based on these criteria yielded 34 studies, which were then reviewed. Results Exosomes can be derived from a variety of biological sources and show potential application in wound healing, scar prophylaxis, photodamage prevention, skin regeneration, improved grafting success, hair loss mitigation, and as biomarkers and drug carriers. Conclusion Exosomes are gaining traction in regenerative and cosmetic dermatology. However, their widespread clinical application is hindered by cost, a complex isolation process, lack of uniform protocols, limited assessment of infective potential, and a paucity of clinical evidence. Further research in this area is needed, especially by way of clinical studies evaluating the efficacy of exosome-based treatments on human skin.

The Internet of Things (IoT) is one of the fastest emerging technologies in the industry. It includes diverse applications with different requirements to provide services to users. Secure, low-powered, and long-range transmissions are some of the most vital requirements in developing IoT applications. IoT uses several communication technologies to fulfill transmission requirements. However, Low Powered Wide Area Networks (LPWAN) transmission standards have been gaining attention because of their exceptional low-powered and long-distance transmission capabilities. The features of LPWAN transmission standards make them a perfect candidate for IoT applications. However, the current LPWAN standards lack state-of-the-art security mechanism s because of the limitations of the IoT devices in energy and computational capacity. Most of the LPWAN standards, such as Sigfox, NB-IoT, and Weightless, use static keys for node authentication and encryption. LoRaWAN is the only LPWAN technology providing session key mechanisms for better security. However, the session key mechanism is vulnerable to replay attacks. In this paper, we propose a centralized lightweight session key mechanism for LPWAN standards using the Blom–Yang key agreement (BYka) mechanism. The security of the session key mechanism is tested using the security verification tool Scyther. In addition, an energy consumption model is implemented on the LoRaWAN protocol using the NS3 simulator to verify the energy depletion in a LoRaWAN node because of the proposed session key mechanisms. The proposed session key is also verified on the Mininet-WiFi emulator for its correctness. The analysis demonstrates that the proposed session key mechanism uses a fewer number of transmissions than the existing session key mechanisms in LPWAN and provides mechanisms against replay attacks that are possible in current LPWAN session key schemes.

We evaluated the performance of oral swab specimen both health-care worker (HCW) collected and self-collected for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detection with rapid antigen test (RAT) as compared to reverse transcriptase polymerase chain reaction (RT-PCR). Of the 529 participants enrolled, 121 (22.8%) were RT-PCR positive. Among the RT-PCR positives, 62 (51.2%) were RAT positive using oral swab. When compared with RT-PCR, RAT with oral swab had sensitivity and specificity of 63.3 and 96.8% respectively among symptomatic individuals. No statistically significant difference was observed in RAT positivity with HCW collection and self-collection, p  = 0.606. Ct values were significantly lower in RT-PCR and RAT positive samples (ORF gene: 18.85 ± 4.36; E gene: 18.72 ± 4.84) as compared to RT-PCR positive and RAT negative samples (ORF gene: 26.98 ± 7.09; E gene: 26.97 ± 7.07), p  < 0.0001. Our study demonstrated moderate sensitivity of RAT with oral swab in symptomatic individuals. Oral swab was the preferred sampling by almost all participants in terms of convenience and comfort as compared to nasopharyngeal swab. Oral swabs have utility for SARS-CoV-2 antigen detection among symptomatic individuals residing in remote rural areas and can serve as an initial screening tool during COVID-19 spikes when cases rise exponentially and laboratory capacities for RT-PCR testing become overwhelmed.

Vitiligo is a chronic autoimmune-mediated disease characterised by the loss of pigmentary cells in the epidermis associated with comorbidity and reductions in quality of life. The pathology of vitiligo is theorized to be multimodal including auto-reactive CD8+ T-cells and inflammatory mediators including IFN-γ and interleukins 2, 6, 15, 17, and 33. Novel treatment options are aimed at restoring pigmentation through procedures (grafting), phototherapy, stem cells, anti-inflammatories and antioxidants. Abstract Vitiligo is a chronic autoimmune-mediated disease characterised by the loss of pigmentary melanocytes in the epidermis. Vitiligo is associated with loss of functional epithelium and significant reductions in quality of life with limited long-term treatment options, highlighting a continued unmet clinical need. A comprehensive understanding of the pathophysiology and newly investigated treatment pathways may guide multimodal treatment strategies and identify future drug targets. The pathology of vitiligo is multifactorial; however, environmental insults in genetically susceptible populations may lead to disease development. Autoreactive CD8+ T-cells that target melanocytes and release inflammatory mediators, including interferon-γ and interleukins 2, 6, 15, 17 and 33 among others, have been identified in vitiligo pathogenesis. Treatment modalities for vitiligo revolve around six broad disease concepts, including procedural modalities (tissue and cellular grafting), phototherapy, stem cells, anti-inflammatories, genetic polymorphisms and antioxidants/vitamins/herbals. Genetic polymorphisms, such as catalase gene variations and toll-like receptor polymorphisms, along with stem cell targets such as melanocytes derived from stem cells, have been implicated in vitiligo onset and possible treatment. Novel JAK-STAT inhibitors have been recently investigated for vitiligo, whereas topical corticosteroids and calcineurin inhibitors continue to be used. Vitamin D, vitamin E, zinc, copper, piperine, pseudo catalase and other vitamins/herbals may improve vitiligo outcomes primarily through antioxidant supplementation pathways. Future studies should investigate alternative drug pathways and targets implicated in vitiligo in large patient cohorts, as well as treatments that target suspected causative immune cells, including memory T-cells, which may provide long-lasting disease-free remission.

Reflectance confocal microscopy (RCM) is an in-vivo, non-invasive imaging modality that provides a high-resolution image of the epidermis and upper dermis. RCM has been utilized as a diagnostic aid for several inflammatory, infectious, and malignant skin conditions; however, its use for clinical and aesthetic skin purposes has not been well established. The purpose of this review is to describe the landscape of RCM utilization for the application of aesthetic skin conditions. A comprehensive literature search was conducted using PubMed using the search terms “reflectance confocal microscopy cosmetic”, and “reflectance confocal microscopy aesthetic”. The search was limited to clinical and animal studies published in English in the last 10 years. RCM must have been utilized to measure an aesthetic dermatological outcome to be eligible for the review. After data abstraction, a total of 46 studies that met the inclusion criteria were identified. The most common utilization of RCM for cosmetic conditions included treatment monitoring and skin morphologic characterization. The primary skin conditions evaluated included skin aging, pigmentation, skin dryness, irritated, and sensitive skin related conditions. Treatment monitoring was primarily conducted for topical agents for skin hydration, skin UV protection, acne, skin dryness, and skin pigmentation purposes. Identification of histo-structural correlations with aesthetic skin conditions may pave the way for future aesthetic drug development. As the popularity of cosmetic dermatologic procedures continues to increase, utilization of RCM for skin characterization and treatment monitoring may be beneficial.